Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $808.1 million.

  • Ocular Therapeutix's Liabilities and Shareholders Equity rose 7645.67% to $808.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year increase of 358.47%. This contributed to the annual value of $808.1 million for FY2025, which is 7645.67% up from last year.
  • Ocular Therapeutix's Liabilities and Shareholders Equity amounted to $808.1 million in Q4 2025, which was up 7645.67% from $410.9 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Liabilities and Shareholders Equity high stood at $808.1 million for Q4 2025, and its period low was $122.6 million during Q2 2023.
  • In the last 5 years, Ocular Therapeutix's Liabilities and Shareholders Equity had a median value of $236.9 million in 2021 and averaged $315.6 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Liabilities and Shareholders Equity tumbled by 3147.23% in 2023, and later surged by 32191.53% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Liabilities and Shareholders Equity stood at $204.9 million in 2021, then fell by 27.14% to $149.3 million in 2022, then skyrocketed by 68.84% to $252.1 million in 2023, then skyrocketed by 81.68% to $457.9 million in 2024, then skyrocketed by 76.46% to $808.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $808.1 million in Q4 2025, compared to $410.9 million in Q3 2025 and $451.3 million in Q2 2025.